Literature DB >> 24337070

NEDD9 regulates 3D migratory activity independent of the Rac1 morphology switch in glioma and neuroblastoma.

Jessie Zhong1, Cuc T Bach, Michael S Y Shum, Geraldine M O'Neill.   

Abstract

UNLABELLED: Metastasizing tumor cells must transmigrate the dense extracellular matrix that surrounds most organs. The use of three-dimensional (3D) collagen gels has revealed that many cancer cells can switch between different modes of invasion that are characterized by distinct morphologies (e.g., rounded vs. elongated). The adhesion protein NEDD9 has the potential to regulate the switch between elongated and rounded morphologies; therefore, its role was interrogated in the invasion switch of glioblastoma and neuroblastoma tumors that similarly derive from populations of neural crest cells. Interestingly, siRNA-mediated depletion of NEDD9 failed to induce cell rounding in glioma or neuroblastoma cells, contrasting the effects that have been described in other tumor model systems. Given that Rac1 GTPase has been suggested to mediate the switch between elongated and rounded invasion, the functionality of the Rac1 morphology switch was evaluated in the glioma and neuroblastoma cells. Using both dominant-negative Rac1 and Rac1-specific siRNA, the presence of this morphologic switch was confirmed in the neuroblastoma, but not in the glioma cells. However, in the absence of a morphologic change following NEDD9 depletion, a significant decrease in the cellular migration rate was observed. Thus, the data reveal that NEDD9 can regulate 3D migration speed independent of the Rac1 morphology switch. IMPLICATIONS: NEDD9 targeting is therapeutically viable as it does not stimulate adaptive changes in glioma and neuroblastoma invasion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337070     DOI: 10.1158/1541-7786.MCR-13-0513

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  7 in total

Review 1.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

2.  Rac GTPase regulation of 3D invasion in neuroblastomas lacking MYCN amplification.

Authors:  Camilla B Mitchell; Geraldine M O'Neill
Journal:  Cell Adh Migr       Date:  2016-05-25       Impact factor: 3.405

3.  Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.

Authors:  Tim N Beck; Emmanuelle Nicolas; Meghan C Kopp; Erica A Golemis
Journal:  Oncoscience       Date:  2014-07-23

4.  Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients.

Authors:  Ningrong Ye; Nian Jiang; Chengyuan Feng; Feiyifan Wang; Hanwen Zhang; Harrusin Xiao Bai; Li Yang; Yandong Su; Chunhai Huang; Siyi Wanggou; Xuejun Li
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

Review 5.  Biomimetic Hydrogels in the Study of Cancer Mechanobiology: Overview, Biomedical Applications, and Future Perspectives.

Authors:  Ayse Z Sahan; Murat Baday; Chirag B Patel
Journal:  Gels       Date:  2022-08-10

6.  Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models.

Authors:  Georgina A Cardama; Julian Maggio; Lucas Valdez Capuccino; Nazareno Gonzalez; Valentina Matiller; Hugo H Ortega; German R Perez; Ignacio A Demarco; Eduardo Spitzer; Daniel E Gomez; Pablo Lorenzano Menna; Daniel F Alonso
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

7.  Cooperative cell invasion: matrix metalloproteinase-mediated incorporation between cells.

Authors:  Camilla B Mitchell; Geraldine M O'Neill
Journal:  Mol Biol Cell       Date:  2016-09-07       Impact factor: 4.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.